Instituto Hermes Pardini S.A.
PARD3.SA
B3 S.A.20.25
BRL
- -
- -
ISIN
BRPARDACNOR1
Return %
Stock
S&P500
1Y
3.23
26.57
3Y
14.96
76.60
5Y
17.15
78.48
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Roberto Santoro Meirelles
- Full Time Employees
- 7,500
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- Rua Aimorés, No. 66 Belo Horizonte MG Brazil 30140-070
- IPO Date
- Feb 14, 2017
- Website
- hermespardini.com.br
- Similar Companies
- Business
- Instituto Hermes Pardini S.A. is a Brazilian healthcare company specializing in medical diagnostic services. Founded in 1959 and headquartered in Belo Horizonte, Brazil, the company provides clinical analysis tests; diagnostic imaging; vaccination; toxicological examinations; medical and dental laboratory research; forensic toxicology; personalized medicine diagnostics; cardiometabolic examinations; DNA screening tests; pathological anatomy; and ancillary diagnostic and therapeutic services. It operates through multiple brands including Hermes Pardini, Progenética, Diagnóstika, Biocod, DLE, Labfar, Toxicologia Pardini, and Solução, serving hospitals, clinics, laboratories, and other healthcare sector entities primarily in the states of Minas Gerais, Goiás, São Paulo, and Rio de Janeiro. In recent major developments, Instituto Hermes Pardini S.A. was acquired by Fleury S.A. in a transaction completed in April 2023, valued at approximately BRL 2.4 billion. This strategic acquisition positions the combined entity as a leading diagnostic medicine group in Brazil and Latin America. In 2024 and 2025, the company has pursued further business integration and expansion, including the acquisition of a 99% stake in CSV Central Sorológica de Vitória for BRL 17.8 million and the merger of CIP - Centro de Infusões Pacaembu Ltda., aiming at cost reduction and business synergy enhancement. Additionally, Hermes Pardini continues to structure innovation programs to enhance its diagnostic and analytic capabilities. Instituto Hermes Pardini operates 124 diagnostic centers across key Brazilian states and maintains an extensive lab-to-lab service offering that includes specialized tests, consulting, training, and support services. It employs approximately 7,500 people and is recognized as a reference in diagnostic medicine in Brazil. Besides its operational footprint in Brazil, the company has broadened its portfolio through subsidiaries and brands that provide forensic toxicology, veterinary diagnostics, cryopreservation, and vaccination services, targeting a diverse client base of healthcare providers and corporate customers within the medical diagnostics industry. This comprehensive diagnostic and healthcare service portfolio, combined with recent strategic acquisitions and its integration into the Fleury group, places Instituto Hermes Pardini S.A. as a key player in Brazil’s healthcare diagnostics market with expanding service coverage and innovation focus.